The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis of Pluvicto.

Basel, March 28, 2025 – Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto ® (lutetium Lu 177 vipivotide tetraxetan) for patients with prostate-specific ...

It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful radiographic progression-free survival benefit ...

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S ...

In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

Novartis said Pluvicto demonstrated positive result in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...